Kurser indlæses...
Prognose
Analytikernes gennemsnitlige kursmål er 131,13 € (+26,70 %). Medianen er 139,81 € (+35,08 %).
| Køb |
22 |
| Behold |
0 |
| Sælg |
0 |
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
AstraZeneca offers about $10 billion for Rhythm Pharmaceuticals
AstraZeneca has reportedly made a takeover offer of about $10 billion for Rhythm Pharmaceuticals, equivalent to $124 per share. Rhythm develops the drug IMCIVREE (active ingredient Setmelanotid) for rare causes of obesity and recorded $92.1 million in revenue in the third quarter, an increase of 29 percent from the previous quarter. Analysts see blockbuster potential for IMCIVREE, meaning AstraZeneca’s offer would strengthen its position in the metabolic field. » Mere på deraktionaer.de
Rhythm Pharmaceuticals: launch of IMCIVREE for hypothalamic obesity gains momentum
Rhythm Pharmaceuticals said at the Wells Fargo conference that the launch of IMCIVREE for hypothalamic obesity is in the “second quarter” of rollout and that there are already about 400 prescriptions from roughly 300 physicians. The company sees hypothalamic obesity (HO), Bardet‑Biedl syndrome and Prader‑Willi syndrome as strategic growth areas and reported positive Phase II data in Prader‑Willi that support Phase III planning. Rhythm stressed it is well capitalized and does not need to raise funds in the near term, but cited access to endocrinologists and the need for multiple studies in Prader‑Willi as operational challenges. The company is also developing follow‑on programs (RM‑718, Bivamelagon) to strengthen the pipeline and long‑term competitive position. » Mere på de.investing.com
Rhythm Pharmaceuticals receives Japanese approval for Imcivree to treat acquired hypothalamic obesity
Japan’s Ministry of Health, Labour and Welfare has approved Imcivree (setmelanotid) from Rhythm Pharmaceuticals for the treatment of acquired hypothalamic obesity, the first approved therapy for this form in Japan. Rhythm estimates the patient population in Japan at 5,000–8,000 and plans to launch the product before the end of 2026, depending on pricing. The approval is based on the phase‑3 TRANSCEND study, which showed a placebo‑adjusted BMI reduction of 18.8%; Imcivree is already approved in the US and the EU. » Mere på de.investing.com
Rhythm Pharmaceuticals: US launch of IMCIVREE gains momentum
Rhythm reports that the US launch of IMCIVREE for acquired hypothalamic obesity is showing strong early demand, with more than 400 therapy requests in 14 weeks and prescriptions from over 300 physicians. About two-thirds of requests were approved by quarter-end; coverage policies account for roughly 25% of commercially insured and 35% of Medicaid beneficiaries. The company holds about $330 million in cash, sufficient for roughly 24 months, and does not see a near-term need for an equity raise. Rhythm is also advancing a pipeline of MC4R agonists, plans Phase III strategies for Prader-Willi before the end of 2025, and intends to further develop bivamelagon and other programs globally. » Mere på de.investing.com
Rhythm Pharmaceuticals: positive Phase 2 data for RM-718 show 11.6% average BMI reduction
Rhythm Pharmaceuticals reports preliminary Phase 2 results for the once‑weekly MC4R agonist RM‑718 in 11 patients with acquired hypothalamic obesity. Seven patients who completed 16 weeks showed an average BMI reduction of 11.6%, stronger than comparator values for bremelanotide (bivamelagon) (10.1% after 14 weeks) and setmelanotide (10.1% after 16 weeks). There were two mild cases of local hyperpigmentation at the injection site and common adverse events such as injection‑site reactions, nausea and vomiting; two patients discontinued due to adverse events. RM‑718 is designed for high selectivity with sparing of MC1R to reduce hyperpigmentation. Rhythm will hold a conference call on Q2 financial results. » Mere på de.investing.com
Virksomhedstal
| (EUR) | september 2026 | YoY |
|---|---|---|
| Omsætning | 81,34 mio. | 86,07 % |
| Bruttofortjeneste | 70,59 mio. | 80,89 % |
| Nettoresultat | -36,52 mio. | 18,98 % |
| EBITDA | -32,02 mio. | 21,31 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 7,24 mia. € |
Antal aktier | 69,33 mio. |
Højeste/laveste i 52 uger | 110,94 € - 67,64 € |
| Udbytte | Nej |
Beta | 2,13 |
P/E (PE Ratio) | -39,66 |
PEG (PEG Ratio) | -6,20 |
K/I (PB Ratio) | 39,40 |
P/S (PS Ratio) | 28,40 |
Virksomhedsprofil
Rhythm Pharmaceuticals, Inc., et biofarmaceutisk selskab i den kommercielle fase, fokuserer på udvikling og kommercialisering af terapier til behandling af sjældne genetiske fedmesygdomme. Selskabets førende produktkandidat er IMCIVREE, en potent melanocortin-4-receptor til behandling af pro-opiomelanocortin (POMC)-, proprotein convertase subtilisin/kexin type 1-, leptinreceptor (LEPR)-mangelfedme samt Bardet-Biedl- og Alströms syndrom. Selskabet udvikler desuden setmelanotid, som er i fase II-kliniske forsøg til behandling af POMC- eller LEPR-heterozygot mangelfedme, steroidreceptor-coaktivator 1-mangelfedme, SH2B1-mangelfedme, MC4-receptor-mangelfedme, Smith-Magenis syndrom-fedme, POMC-epigenetiske lidelser og andre MC4R-lidelser. Rhythm Pharmaceuticals, Inc. har en samarbejdsaftale om forskning med Clinical Registry Investigating Bardet-Biedl Syndrome. Selskabet var tidligere kendt som Rhythm Metabolic, Inc. og ændrede navn til Rhythm Pharmaceuticals, Inc. i oktober 2015. Rhythm Pharmaceuticals, Inc. blev grundlagt i 2008 og har hovedkontor i Boston, Massachusetts.
| Navn | Rhythm Pharmaceuticals Inc |
| CEO | David Meeker |
| Hjemsted | Boston,
ma USA |
| Websted | |
| Sektor | Materialer |
| Branche | Kemikalier |
| Børsnotering | 09.10.2017 |
| Medarbejdere | 414 |
Tickersymboler
| Børs | Symbol |
|---|---|
NASDAQ | RYTM |
Frankfurt | 1RV.F |
Düsseldorf | 1RV.DU |
München | 1RV.MU |